

Iran (Islamic Republic of)

COUNTRY GENERAL INFORMATION

Total population:	80 673 888
Gender F/M (%):	49.4 / 50.6
Population, age group <15 / ≥ 15 years (%):	24 / 76
Life expectancy at birth (F/M, years):	79 / 75
GDP (PPP int \$):	21 011
Income status:	Upper middle income
Number of 1 st sub-national administrative level divisions, name:	31, Province (Ostan)



EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	54	1659	10 710	0
Number of relapses: ¹	0	36	44	N/A
Total number of cases:	60	1721^A	10 770^B	0
Imported cases (#, %):	0, 0%	5, 0%	200, 2%	N/A
Gender distribution (% F):	40	50	39	N/A
Age group distribution (% <5 / 5-14 / >14):	57 / 7 / 30	11 / 23 / 66	16 / 19 / 65	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.05	1.73	1.95	N/A
Number of endemic 1 st sub-national administrative level divisions:	4	2	18	N/A
Population at risk (% # at risk / total population): ²	14% 11 014 000/ 80 673 888	12% 9 768 000/ 80 673 888	68% 55 039 000/ 80 673 888	N/A
Was there any outbreak?	No	No	No	N/A
Number of new foci: ³	0	0	0	N/A



Monthly distribution of new cases (January-December)^C

2017	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	7	5	4	2	4	3	3	6	2	0	3	1
ACL	129	150	137	173	182	145	131	105	114	115	136	142
ZCL	1397	1113	763	484	402	365	307	639	943	1331	1514	1417

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and Incidence rate/10 000 at the national level from 2002 to 2017



¹Includes 26 cases classified as "unspecified"

²Includes 16 cases classified as "unspecified"


³For cases with available subnational monthly data reported

⁴Relapse in this country is defined for VL as: "Cure at the end of treatment and recurrence the clinical sign" and for CL as: "recurrence of cutaneous lesion after healed"

⁵Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

⁶Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL, ACL and ZCL cases at Province level per 10 000 population (2017)



CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2007
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin
Year latest national guidelines (CL / VL):	2007 / 2007
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	170 / 460

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	0	0	N/A
Number of people screened passively for:	No data	1685	8525	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	0% (0/60)	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data (0/0)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	30% (18/60)	100% (1683/1685)	76% (8157/10726)	N/A
Proportion of positive slides (% , # slides + / total slides):	No data (18/0)	100% (1683/1685)	96% (8157/8525)	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	0% (0/60)	N/A	24% (2569/10726)	N/A
Percentage of cases with HIV-VL coinfection:	0% (0/60)	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	110% (66/60)	51% (861/1685)	67% (7239/10726)
Initial cure rate (% , # cases initially cured / new cases):	100% (60/60)	51% (861/1685)	67% (7239/10726)
Failure rate (% , # cases with treatment failure / new cases): ⁴	0% (0/60)	2% (26/1685)	0% (30/10726)
Case fatality rate (% , # cases who died / new cases):	0% (0/60)	0% (0/1685)	0% (0/10726)

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

⁷Failure in this country is defined for VL as: "Case with no cure at the end of treatment" and for CL as: "Absence of healing presentation at the end of treatment"